| Followers | 200 |
| Posts | 25596 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, January 15, 2022 2:16:08 PM
There are many things that would be material events or material developments to shareholders. For most, regular reporting requirements in Quarterly and Annual reporting documentation take care of them, and for a narrow set of developments deemed highly consequential, by rule, one would consult the 8-K instructions, as that provides for immediate or earlier disclosure for that narrow set of material events.
https://www.sec.gov/files/form8-k.pdf
It also allows companies discretion to use the 8-K disclosure for events of note that do not require immediate disclosure.
Some shareholders think every material event or event that an ordinary shareholder would want to know is subject to immediate disclosure, this is not the case, though bulletin boards love to advance this view. But it is also very possible that a company can choose to disclose events that happen that are not required but would seem worthwhile to make note of to the investment world as a very important development.
This is not to disagree with anyone, but to lay out the circumstances more clearly in order to have a more intelligent discussion.
https://www.sec.gov/files/form8-k.pdf
It also allows companies discretion to use the 8-K disclosure for events of note that do not require immediate disclosure.
Some shareholders think every material event or event that an ordinary shareholder would want to know is subject to immediate disclosure, this is not the case, though bulletin boards love to advance this view. But it is also very possible that a company can choose to disclose events that happen that are not required but would seem worthwhile to make note of to the investment world as a very important development.
This is not to disagree with anyone, but to lay out the circumstances more clearly in order to have a more intelligent discussion.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
